Home Psychedelic Stock Review Cybin (CLXPF CYBN) Gets $8.00 Price Target From H.C. Wainwright. Biotech NewsInstitutional Analyst NewsletterPsychedelic NewsPsychedelic Stock Review Cybin (CLXPF CYBN) Gets $8.00 Price Target From H.C. Wainwright. By Editor / Curator - July 26, 2021 Facebook Twitter Google+ Pinterest Linkedin Email Advancing Multiple Psychedelics in Multiple Indications; Initiating With a Buy and $8 Price Target. REPORT LIVE QUOTE INVESTOR DECK RELATED ARTICLESMORE FROM AUTHOR All News Experts From Harvard, Scripps Research Institute, the University Hospital Zürich, and the Former Chief Science Officer at Immunogen – Join Tharimmune (THAR). Mpox Major Mpox Outbreak in the Democratic Republic of Congo. All News Mpox Infections Rise to Almost Double Last Year’s Numbers. All News Adding Asia Broadband (AABB) to Speculative Watch List. 2024 Watch List GeoVax to Present at World Vaccine Congress, Thursday April 4th. All News Post Reverse Split, Tharimmune (THAR) Announces Positive Phase I Results. Latest article Experts From Harvard, Scripps Research Institute, the University Hospital Zürich, and the Former Chief... All News Editor / Curator - April 17, 2024 Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody... Major Mpox Outbreak in the Democratic Republic of Congo. Mpox Editor / Curator - April 3, 2024 As Reported in NPR's Gates and Soda Major Mpox Outbreak in the Democratic Republic of Congo is a... Mpox Infections Rise to Almost Double Last Year’s Numbers. All News Editor / Curator - April 3, 2024 The number of mpox cases in 2024 is already nearly double the number of cases that were detected in all of...